Facio presents at the 6th annual Orphan Drugs and Rare Diseases Europe Conference

May 5, 2017

Facio Therapies will present its mission to improve the lives of people with FSHD, and showcase the latest results from its FSHD drug discovery program at the 6th annual Orphan Drugs and Rare Diseases Europe Conference in Berlin, Germany, on May 15th, 2017.  

The 6th annual Orphan Drugs and Rare Diseases Europe Conference, is organized by SMI and connects the different stakeholders in the rare disease industry including patient advocates, regulators, pharma, investors and academia. Facio’s Managing Director, David Dasberg, will discuss Facio’s origin, the translation of science into early stage drug discovery, as well as community alignment. Facio’s Case Study: “Breaking Through to an FSHD Therapy” will be held at the Crowne Plaza Berlin – Potsdamer Platz, Berlin, Germany on May 15th, 2017 at 16:30 (CEST).

About Facio Therapies

Arising from the FSHD community, Facio aims to translate breakthrough results of 25 years of basic research into a therapy that stops the progressive muscle wasting caused by FSHD. That is Facio’s product mission. Facio also aims to make its therapy widely available by using a transparent model for fair and reimbursable pricing. That way, Facio aims to generate sustainable profits to fund additional quality-of-life projects for people with FSHD and to provide liquidity to its shareholders. That is Facio’s socio-economic mission.